Standard Life Reveals Brits Think They Cannot Live on £140 a Week

Standard Life’s new research* has revealed that almost two out of three people (63%) think they could not live on £140 a week in retirement, rising to 72% for the 55 and over’s. Only 17% of the 55 and over’s think they could live on £140 a week. The Government has recently proposed a single-tier flat-rate state pension worth around £140 a week, and are currently consulting on how this might be introduced in 2015 at the earliest.

John Lawson, head of pensions policy at Standard Life said: “The introduction of state pensions of £140 a week for all is to be welcomed. This makes it clear and easy for people to understand what they will receive from the government as a pension. However, people clearly recognise that£140 a week will not likely be enough to live on in retirement.”

The research also found there were significant differences of opinion between age groups, with the young more likely to think £140 a week was OK, while those in the older age ranges having had a reality check at the cost of living.

John Lawson concluded with tips for improving overall financial health: “Set up a savings plan to put money away for your future needs. Pensions and are enough to meet the savings needs of 99% of the population. If you are saving for a retirement income, a pension is the most tax efficient home for your money.

“Investing in cash, whilst generally safe, often means that your savings don’t even keep pace with inflation, so don’t be afraid to take some risk, particularly if you are investing for the longer-term. Savings providers now offer personalised investment portfolios, such as Standard Life’s MyFolio, that match the level of risk you are comfortable with.”

Via EPR Network
More Financial press releases

Saxo Bank Provides Retail Derivatives Trading to TD Waterhouse

Saxo Bank, the specialist in online trading and investment, has announced it will provide TD Waterhouse, the UK’s leading execution only broker, with an online derivatives trading platform for retail investors. Through Saxo Bank’s technology and service, TD Waterhouse will enhance its offering to enable customers to take control of their trading through TD Derivatives Trading for Contracts for Differences (CFDs), FX and Futures.

The TD Derivatives Trading account, which will be provided by Saxo Bank, has been developed to respond to the needs of sophisticated derivatives traders. Clients can tradeCFDs with commissions starting from 0.15% (minimum £15) on all markets. They can also take advantage of one of the leading FX Trading offerings available, with access to more than 160 FX currency pairs. The account also includes Futures, enabling customers to trade over 450 instruments on live market prices from exchanges around the world. TD Derivatives Trading clients can also create their perfect trading environment using two, free customisable platforms that can be adapted to their exact specifications.

Darren Hepworth, trading and customer services director at TD Waterhouse commented: “We always strive to ensure our customers have access to the best products and services. With the launch of TD Derivatives Trading, our customers can take control of their trading needs and create their perfect trading environment.”

Albert Maasland, CEO of Saxo Bank London added: “We are thrilled to be working with the preeminent execution only broker, TD Waterhouse. Their decision to adopt Saxo Bank’s technology and service are testament to the effectiveness of our offering in the retail market place. We strive to develop a collaborative business model, and the launch of this service reinforces the strength of our Institutional solutions.”

Via EPR Network
More Financial press releases

Business Monitor International Launches Report on China’s Pharmaceutical and Healthcare Industry

Business Monitor International (BMI) has announced its latest report, China Pharmaceuticals & Healthcare Report.

The healthcare and pharmaceutical analysis includes Business Monitor International’s five and ten year forecast for drugs and healthcare expenditure, imports and exports, and focuses on the growth outlook for the prescription, OTC, patented drugs and generics market segments. The forecasts are based on in depth analysis into industry trends and new developments.

The China Analysis report is designed to provide industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Chinese pharmaceutical and healthcare industry. The report is vital to these groups so that they can benchmark BMI’s independent five and ten year pharmaceutical and healthcare industry forecasts on Chine, target business opportunities and risks in the Chinese pharmaceutical and healthcare sector and asses the activities, strategy and market position of pharmaceutical competitors, partners and clients.

Following the outcome of Q1 2011, BMI now predicts China will become the most attractive pharmaceutical market in Asia Pacific within the next five years. China has the world´s most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by political stability, demand for medicines, both generic and patented, will continue to increase. However – the key downside risk is further pricing pressures, which could intensify in the event of an economic slowdown.

Via EPR Network
More Financial press releases